Fulvestrant - a novel endocrine therapy for breast cancer.

Fulvestrant is a novel endocrine therapy for breast cancer, with a unique structure and mode of action. It binds competitively to the oestrogen receptor (ER), with high affinity, and downregulates ER by functional blockade and increased turnover. Fulvestrant has reached the clinic via extensive pre-clinical and clinical trials, which demonstrated fulvestrant's unique characteristics and showed that they translate to equivalent or improved clinical efficacy compared to established endocrine agents. Fulvestrant is currently licensed for use in postmenopausal women with hormone receptor positive advanced breast cancer which has progressed on prior endocrine therapy. As a pure oestrogen antagonist, fulvestrant avoids the risk of detrimental side effects of selective ER modulators such as tamoxifen, which has partial agonist activity. Fulvestrant, the only parenteral agent in this setting, has a good side effect profile and is well tolerated. Due to its unique mode of action, fulvestrant lacks cross-resistance with existing agents. Fulvestrant is the subject of much ongoing research, which utilises knowledge of its novel mechanism and pharmacokinetic profile in order to optimise clinical efficacy and explore new roles, including first-line use in advanced breast cancer, use in combination with existing agents, in males, and in premenopausal women, and use as an adjuvant therapy.

[1]  M. Lichinitser,et al.  CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. , 2009 .

[2]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Cheung,et al.  The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma , 2008, World journal of surgical oncology.

[4]  M. Piccart,et al.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Cheung.  Endocrine therapy for breast cancer: an overview. , 2007, Breast.

[6]  R. Eastell,et al.  Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant , 2006 .

[7]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Ellis,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.

[9]  C. Osborne,et al.  Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. , 2003, European journal of cancer.

[10]  R. Yates,et al.  A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers , 2002, British Journal of Cancer.

[11]  Wolfgang Eiermann,et al.  An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane , 2002, Cancer.

[12]  G. Hortobagyi,et al.  Breast Cancer in Men , 2002, Annals of Internal Medicine.

[13]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Dowsett,et al.  Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer , 2001 .

[15]  R. Penson,et al.  Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Fehrenbacher,et al.  Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer , 1999 .

[17]  A. Howell,et al.  Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer , 1997 .

[18]  V. Jordan,et al.  Gynecologic effects of tamoxifen and the association with endometrial carcinoma , 1995, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[20]  J. Feyzi,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.

[21]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[22]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[23]  H. Huynh,et al.  Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. , 1993, Cancer research.

[24]  A. Wakeling,et al.  ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[27]  M. Johnson,et al.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.

[28]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Wakeling,et al.  Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. , 1989, Journal of molecular endocrinology.

[30]  B. Katzenellenbogen,et al.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.

[31]  A. Wakeling,et al.  Steroidal pure antioestrogens. , 1987, The Journal of endocrinology.

[32]  P. Rosen,et al.  Tamoxifen flare in advanced breast cancer. , 1978, JAMA.

[33]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.

[34]  J. Robertson,et al.  Fulvestrant in Advanced Male Breast Cancer , 2006, Breast Cancer Research and Treatment.

[35]  L. Parker,et al.  Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer , 2004, Clinical pharmacokinetics.